BACKGROUND AND AIM: Worldwide, 1,470,900 women are diagnosed yearly with a gynecological malignancy (21,000 in the UK). Some patients treated with pelvic radiotherapy develop chronic changes in their bowel function. This systematic review summarizes current research on the impact of cancer treatment on the gut and vaginal microbiome in women with a gynecological malignancy. METHODS: The Preferred reporting Items for Systematic Reviews and Meta-analyses guidelines for systematic reviews were used to ensure transparent and complete reporting. Quantitative studies exploring the gut or vaginal microbiome in this patient cohort were included. Animal studies were excluded. There were no language restrictions. RESULTS: No studies examined the possible effects of surgery or chemotherapy for gynecological cancers on the gut or vaginal microbiome.Three prospective cohort studies were identified using sequencing of changes in the gut microbiome reporting on a total of 23 women treated for gynecological cancer. All studies included patients treated with radiotherapy with a dosage ranging from 43.0 to 54.0 Gy. Two studies assessed gastrointestinal toxicity formally; 8 women (57%) developed grade 2 or 3 diarrhea during radiotherapy. The outcomes suggest a correlation between changes in the intestinal microbiome and receiving radiotherapy and showed a decrease in abundance and diversity of the intestinal bacterial species. Before radiotherapy, those who developed diarrhea had an increased abundance of Bacteroides, Dialister, and Veillonella (P < 0.01), and a decreased abundance of Clostridium XI and XVIII, Faecalibacterium, Oscillibacter, Parabacteroides, Prevotella, and unclassified bacteria (P < 0.05). CONCLUSION: The limited evidence to date implies that larger studies including both the vaginal and gut microbiome in women treated for a gynecological malignancy are warranted to explore the impact of cancer treatments on the microbiome and its relation to developing long-term gastrointestinal toxicity. This may lead to new avenues to stratify those at risk and explore personalized treatment options and prevention of gastrointestinal consequences of cancer treatments.
BACKGROUND AND AIM: Worldwide, 1,470,900 women are diagnosed yearly with a gynecological malignancy (21,000 in the UK). Some patients treated with pelvic radiotherapy develop chronic changes in their bowel function. This systematic review summarizes current research on the impact of cancer treatment on the gut and vaginal microbiome in women with a gynecological malignancy. METHODS: The Preferred reporting Items for Systematic Reviews and Meta-analyses guidelines for systematic reviews were used to ensure transparent and complete reporting. Quantitative studies exploring the gut or vaginal microbiome in this patient cohort were included. Animal studies were excluded. There were no language restrictions. RESULTS: No studies examined the possible effects of surgery or chemotherapy for gynecological cancers on the gut or vaginal microbiome.Three prospective cohort studies were identified using sequencing of changes in the gut microbiome reporting on a total of 23 women treated for gynecological cancer. All studies included patients treated with radiotherapy with a dosage ranging from 43.0 to 54.0 Gy. Two studies assessed gastrointestinal toxicity formally; 8 women (57%) developed grade 2 or 3 diarrhea during radiotherapy. The outcomes suggest a correlation between changes in the intestinal microbiome and receiving radiotherapy and showed a decrease in abundance and diversity of the intestinal bacterial species. Before radiotherapy, those who developed diarrhea had an increased abundance of Bacteroides, Dialister, and Veillonella (P < 0.01), and a decreased abundance of Clostridium XI and XVIII, Faecalibacterium, Oscillibacter, Parabacteroides, Prevotella, and unclassified bacteria (P < 0.05). CONCLUSION: The limited evidence to date implies that larger studies including both the vaginal and gut microbiome in women treated for a gynecological malignancy are warranted to explore the impact of cancer treatments on the microbiome and its relation to developing long-term gastrointestinal toxicity. This may lead to new avenues to stratify those at risk and explore personalized treatment options and prevention of gastrointestinal consequences of cancer treatments.
Authors: Wendy S Garrett; Carey A Gallini; Tanya Yatsunenko; Monia Michaud; Andrea DuBois; Mary L Delaney; Shivesh Punit; Maria Karlsson; Lynn Bry; Jonathan N Glickman; Jeffrey I Gordon; Andrew B Onderdonk; Laurie H Glimcher Journal: Cell Host Microbe Date: 2010-09-16 Impact factor: 21.023
Authors: John K DiBaise; Husen Zhang; Michael D Crowell; Rosa Krajmalnik-Brown; G Anton Decker; Bruce E Rittmann Journal: Mayo Clin Proc Date: 2008-04 Impact factor: 7.616
Authors: H Jervoise N Andreyev; Susan E Davidson; Catherine Gillespie; William H Allum; Edwin Swarbrick Journal: Gut Date: 2011-11-04 Impact factor: 23.059
Authors: Aparna Mitra; Greyson Willis Grossman Biegert; Andrea Y Delgado; Tatiana V Karpinets; Travis N Solley; Melissa P Mezzari; Kyoko Yoshida-Court; Joe F Petrosino; Megan D Mikkelson; Lilie Lin; Patricia Eifel; Jianhua Zhang; Lois M Ramondetta; Anuja Jhingran; Travis T Sims; Kathleen Schmeler; Pablo Okhuysen; Lauren E Colbert; Ann H Klopp Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-25 Impact factor: 7.038
Authors: Raj Kalkeri; Kevin Walters; William Van Der Pol; Braden C McFarland; Nathan Fisher; Fusataka Koide; Casey D Morrow; Vijay K Singh Journal: BMC Microbiol Date: 2021-03-29 Impact factor: 3.605
Authors: Byeongsang Oh; Thomas Eade; Gillian Lamoury; Susan Carroll; Marita Morgia; Andrew Kneebone; George Hruby; Mark Stevens; Frances Boyle; Stephen Clarke; Brian Corless; Mark Molloy; David Rosenthal; Michael Back Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639
Authors: Khiem Chi Lam; Dariia Vyshenska; Jialu Hu; Richard Rosario Rodrigues; Anja Nilsen; Ryszard A Zielke; Nicholas Samuel Brown; Eva-Katrine Aarnes; Aleksandra E Sikora; Natalia Shulzhenko; Heidi Lyng; Andrey Morgun Journal: PeerJ Date: 2018-09-19 Impact factor: 2.984
Authors: Despina Tsementzi; Angela Pena-Gonzalez; Jinbing Bai; Yi-Juan Hu; Pretesh Patel; Joseph Shelton; Mary Dolan; Jessica Arluck; Namita Khanna; Lesley Conrad; Isabelle Scott; Tony Y Eng; Konstantinos T Konstantinidis; Deborah W Bruner Journal: Cancer Med Date: 2020-04-01 Impact factor: 4.452
Authors: Travis T Sims; Molly B El Alam; Tatiana V Karpinets; Stephanie Dorta-Estremera; Venkatesh L Hegde; Sita Nookala; Kyoko Yoshida-Court; Xiaogang Wu; Greyson W G Biegert; Andrea Y Delgado Medrano; Travis Solley; Mustapha Ahmed-Kaddar; Bhavana V Chapman; K Jagannadha Sastry; Melissa P Mezzari; Joseph F Petrosino; Lilie L Lin; Lois Ramondetta; Anuja Jhingran; Kathleen M Schmeler; Nadim J Ajami; Jennifer Wargo; Lauren E Colbert; Ann H Klopp Journal: Commun Biol Date: 2021-02-22